Lupin launches world’s first fixed-dose triple combination drug ‘Vilfuro-G’

23 Nov 2023 Evaluate

Lupin has launched the world’s first fixed-dose triple combination drug (FDC) under the brand name Vilfuro-G for the effective management of chronic obstructive pulmonary disease (COPD) in India. This milestone follows the approval granted by the Drug Controller General of India for the Dry Powder Inhaler (DPI) product.

Lupin Vilfuro-G is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate and Glycopyrronium Bromide, for the long-term management and treatment of moderate to severe COPD. The product is available in a single-strength fixed dose, with a recommended once-daily dosage. This therapeutic innovation by Lupin brings hope to more than 37 million individuals struggling with COPD in India, a condition that ranks among the leading causes of death and disability in the nation.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2061.50 -36.15 (-1.72%)
08-Dec-2025 15:31 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1790.05
Dr. Reddys Lab 1272.70
Cipla 1498.90
Zydus Lifesciences 920.90
Lupin 2061.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×